BRPI0515378A - formulações dermalmente aplicáveis para tratamento de doenças de pele em animais - Google Patents

formulações dermalmente aplicáveis para tratamento de doenças de pele em animais

Info

Publication number
BRPI0515378A
BRPI0515378A BRPI0515378-6A BRPI0515378A BRPI0515378A BR PI0515378 A BRPI0515378 A BR PI0515378A BR PI0515378 A BRPI0515378 A BR PI0515378A BR PI0515378 A BRPI0515378 A BR PI0515378A
Authority
BR
Brazil
Prior art keywords
animals
skin diseases
treating skin
applicable formulations
dermally applicable
Prior art date
Application number
BRPI0515378-6A
Other languages
English (en)
Inventor
Kirkor Sirinyan
Holger Lehmann
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0515378A publication Critical patent/BRPI0515378A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

FORMULAçõES DERMALMENTE APLICáVEIS PARA TRATAMENTO DE DOENçAS DE PELE EM ANIMAIS. A presente invenção refere-se a formulações incluindo um composto tricíclico para o tratamento dermal de doenças de pele em animais.
BRPI0515378-6A 2004-09-16 2005-09-02 formulações dermalmente aplicáveis para tratamento de doenças de pele em animais BRPI0515378A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61049304P 2004-09-16 2004-09-16
PCT/EP2005/009468 WO2006029726A1 (en) 2004-09-16 2005-09-02 Dermally applicable formulations for treating skin diseases in animals

Publications (1)

Publication Number Publication Date
BRPI0515378A true BRPI0515378A (pt) 2008-07-22

Family

ID=35229966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515378-6A BRPI0515378A (pt) 2004-09-16 2005-09-02 formulações dermalmente aplicáveis para tratamento de doenças de pele em animais

Country Status (9)

Country Link
US (1) US20080207670A1 (pt)
EP (1) EP1791522A1 (pt)
JP (1) JP2008513388A (pt)
AU (1) AU2005284422A1 (pt)
BR (1) BRPI0515378A (pt)
CA (1) CA2580286A1 (pt)
MX (1) MX2007002961A (pt)
NO (1) NO20071798L (pt)
WO (1) WO2006029726A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
NZ575118A (en) 2006-09-01 2012-04-27 Du Pont Local topical administration formulations containing indoxacarb and a crystallization inhibitor
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
TW200924647A (en) * 2007-08-30 2009-06-16 Schering Plough Ltd Local topical administration formulations containing fipronil
EP2671583A4 (en) * 2011-01-31 2014-09-03 Univ Osaka EXTERNALLY USED MEDICAMENT FOR THE TREATMENT OF SKIN DISEASES AND MANUFACTURING METHOD THEREFOR
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
CA3186350A1 (en) * 2013-02-27 2014-09-04 Argenta Innovation Limited Transdermal formulations
JP7108631B2 (ja) * 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2021176263A1 (en) 2020-03-02 2021-09-10 Shanghai Aucta Pharmaceuticals Co., Ltd. Topical formulations containing mtor inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
GB9205007D0 (en) * 1992-03-07 1992-04-22 Pfizer Ltd Antiparasitic agents
GB2327610B (en) * 1994-11-04 1999-06-02 Novartis Ag Macrolide compositions
US6426333B1 (en) * 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
GB0126253D0 (en) * 2001-10-31 2002-01-02 Metris Therapeutics Ltd Treatment method
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
MXPA05010659A (es) * 2003-04-04 2005-12-12 Merial Ltd Formulaciones veterinarias antihelminticas topicas.

Also Published As

Publication number Publication date
NO20071798L (no) 2007-04-03
AU2005284422A1 (en) 2006-03-23
US20080207670A1 (en) 2008-08-28
CA2580286A1 (en) 2006-03-23
WO2006029726A1 (en) 2006-03-23
JP2008513388A (ja) 2008-05-01
EP1791522A1 (en) 2007-06-06
MX2007002961A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
BRPI0515378A (pt) formulações dermalmente aplicáveis para tratamento de doenças de pele em animais
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
BRPI0507039A (pt) composição, métodos de tratar um paciente com cáncer, e de inibir a angiogênese em um tumor, e, kit
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
BR0315023B1 (pt) distribuidor de composição anti-séptica de pele.
BRPI0512841A (pt) composições e métodos para o tratamento de infecções patológicas
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
BRPI0506305A (pt) artigos e métodos de tratamento da pele
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
GT200500127A (es) Composiciones y metodos para el tratamiento de trastorno disforico premenstrual
GT200500378A (es) Macrolidos
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
MY145822A (en) Substituted biaryl piperazinyl-pyridine analogues
WO2005089872A3 (en) Treatment of local pain
ATE495728T1 (de) Kosmetische oder dermatologische zubereitungen mit n-acetylcystein
MX2010003474A (es) Esterilizante quimico para control de poblacion de perros macho adultos, que comprende un gluconato mineral y un aminoacido.
IL166016A0 (en) Topical treatment of skin diseases
EA200702026A1 (ru) Лечение или предупреждение зуда
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DE602005017605D1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
MX2011007885A (es) Formulaciones de emulsion de narcoticos para tratamiento de dolor por cancer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired